In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, receive regulatory clearances, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).
Entered a new phase of its partnership with Novo Nordisk to develop advanced cellular medicines for diabetes. Aspect will lead development, manufacturing, and commercialization while integrating select Novo Nordisk technologies and capabilities, strengthening its end-to-end platform for scalable, disease-modifying cell therapies.
Closed $3.7M in an oversubscribed Series Seed Preferred round to advance its integrated electrosurgery device toward FDA 510(k) submission and initial commercialization. The financing supports development of ClearCut Surgical’s single-use, plug-and-play device that combines electrosurgery, smoke evacuation, liquid suction, and blunt dissection to simplify surgical workflows without added capital equipment.
Appointed Michael Alspaugh as Vice President of Commercialization to support the company’s next phase of growth. With three decades of global medtech leadership across renal, MedSurg, and diagnostics markets, Alspaugh brings deep dialysis experience from Gambro, Baxter, and Physidia, along with time at Abbott and Boston Scientific, to help guide Diality’s commercialization strategy.
Closed a $75M Series C financing to accelerate nationwide commercial adoption of its AVENTUS™ Thrombectomy System and advance its next-generation product pipeline. The raise follows a pivotal year for Inquis Medical, marked by expanded regulatory clearance for pulmonary embolism and publication of pivotal trial data demonstrating significant clot removal while minimizing blood loss and no device-related adverse events.
Won Phase 3 of the NIH SPARC Neuromod Prize, securing a $1.6M cash award to support ongoing product development and clinical trials for its neuromodulation therapy targeting mixed urinary incontinence. Separately, the company announced the appointment of medtech executive Frank Fischer to its Board of Directors.
Received FDA clearance for the “Picasso” feature, marking Proprio’s fourth FDA-cleared capability within its Paradigm™ platform. The clearance expands Paradigm's surgeon-controlled, radiation-free registration workflow, enabling trace-based optical registration to support intraoperative spinal alignment measurement across a broader range of spine procedures.
Secured £4.5 million in investment and grant funding to advance development of GRACE, its fully implantable electric field therapy for glioblastoma. The funding supports progression into first-in-human clinical studies, marking a critical step in the company’s mission to improve outcomes for patients with one of the most aggressive and difficult-to-treat brain cancers.
Announced the publication of a peer-reviewed study demonstrating that tissue previously deemed non-salvageable and destined for amputation can stabilize and heal when peripheral neuropathy is directly addressed through a targeted nerve signaling intervention. According to the company, these findings contribute to a growing body of evidence suggesting that peripheral neuropathy plays a critical, and potentially modifiable, role in tissue failure and recovery.
Announced the launch of the FungiFlexⓇ Mold Panel, a plasma-based molecular diagnostic test now available through its CLIA-certified laboratory, enabling detection of cell-free DNA from a single plasma sample, with results delivered in approximately 24 hours from sample receipt. The test identifies 14 clinically important mold species, marking the first clinical offering of Zepto’s rapid, deployable liquid biopsy platform for infectious disease diagnostics.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2026 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy